Abstract
Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.
| Bidragets oversatte titel | Intravitreal angiostatic treatment of ocular vascular diseases |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V04190256 |
| Tidsskrift | Ugeskrift for Læger |
| Vol/bind | 182 |
| Udgave nummer | 10 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2020 |